Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
25.80
-0.40 (-1.53%)
Nov 18, 2026, 12:56 PM EST - Market open
Vera Therapeutics Employees
Vera Therapeutics had 362 employees as of September 30, 2026. The number of employees increased by 138 or 61.61% compared to the same quarter last year. That makes Vera Therapeutics the 22,511th largest employer in the world and 2,919th in the United States.
Employees
362
Change (1Y)
138
Growth (1Y)
61.61%
Revenue / Employee
$28,390
Profits / Employee
-$1,147,273
Market Cap
1.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 362 | 138 | 61.61% |
| Jun 30, 2026 | 361 | 169 | 88.02% |
| Mar 31, 2026 | 339 | 187 | 123.03% |
| Dec 31, 2025 | 249 | 137 | 122.32% |
| Sep 30, 2025 | 224 | 142 | 173.17% |
| Jun 30, 2025 | 192 | 120 | 166.67% |
| Mar 31, 2025 | 152 | 97 | 176.36% |
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Sep 30, 2024 | 82 | 33 | 67.35% |
| Jun 30, 2024 | 72 | 23 | 46.94% |
| Mar 31, 2024 | 55 | 9 | 19.57% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Sep 30, 2023 | 49 | 8 | 19.51% |
| Jun 30, 2023 | 49 | 20 | 68.97% |
| Mar 31, 2023 | 46 | 28 | 155.56% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Sep 30, 2022 | 41 | 26 | 173.33% |
| Jun 30, 2022 | 29 | 16 | 123.08% |
| Mar 31, 2022 | 18 | 6 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Replimune Group | 465 |
| Maravai LifeSciences Holdings | 410 |
| Harmony Biosciences Holdings | 293 |
| Zymeworks | 279 |
| Zenas BioPharma | 167 |
| Maze Therapeutics | 141 |
| Septerna | 134 |
VERA News
- 8 days ago - Vera Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 11 days ago - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Vera Therapeutics price target lowered to $29 from $34 at Wedbush - TheFly
- 12 days ago - Vera Therapeutics price target lowered to $66 from $76 at Guggenheim - TheFly
- 12 days ago - Vera Therapeutics price target lowered to $75 from $90 at H.C. Wainwright - TheFly
- 12 days ago - Vera Therapeutics reports Q3 EPS ($1.30), consensus ($1.62) - TheFly
- 12 days ago - Vera Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 12 days ago - Vera Therapeutics Earnings release: Q3 2026 - Filings